Clinical Trial Update: Positive Surgical Margins Rate and EGFR Family Members Expression in Prostate Cancer Treated With Bicalutamide [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 clinical trial updates report on bicalutamide use in prostate cancer, focusing on positive surgical margins and expression of EGFR family members.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• bicalutamide (bicalutamide)

Snippet

Sponsor: University of L'Aquila | Conditions: Prostate Cancer | Phase 2, Phase 3 | Status: COMPLETED